FIELD: biotechnology.
SUBSTANCE: present invention relates to biotechnology, specifically to recombinant obtaining of proteins and can be used to prepare soluble protein expressed in E. coli. Method includes steps of (i) preparing inclusion bodies in buffer containing from 0 M to about 7 M urea to form suspension of inclusion bodies; (ii) affecting inclusion body suspension by gradual increase in pressure over a period of time and (iii) maintaining high pressure applied to inclusion bodies for a period of time.
EFFECT: with this invention it is possible to increase yield of soluble, disaggregated, refolded active proteins from inclusion bodies.
7 cl, 22 dwg, 3 ex, 13 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| OPTIMISED METHOD OF PURIFYING RECOMBINANT PROTEIN OF GROWTH FACTOR | 2008 |
|
RU2491290C2 |
| METHOD OF EXTRACTING REFOLDED RECOMBINANT PROTEIN FROM PROKARYOTIC CELL CULTURE (VERSIONS) | 2007 |
|
RU2439076C2 |
| FUSION PROTEIN CONTAINING THYMIC STROMAL LYMPHOPOIETIC PROTEIN, VACCINE CONTAINING EXPRESSION VECTOR FOR EXPRESSION OF PROTEINS AND VACCINE COMPRISING SAID EXPRESSION VECTOR | 2012 |
|
RU2617957C2 |
| RECOMBINANT L1HPV16 GENE, RECOMBINANT PQE-L1/16 PLASMID, L1HPV16 PROTEIN AND THEIR APPLICATION | 2016 |
|
RU2628693C1 |
| EXPRESSION SYSTEM AND METHOD OF PRODUCING NON-MODIFIED RECOMBINANT PROTEINS IN Escherichia coli USING IT | 2015 |
|
RU2604796C1 |
| HYBRID PROTEIN-BASED POLYVALENT INFLUENZA VACCINE | 2013 |
|
RU2531235C2 |
| CANINE THYMIC STROMAL LYMPHOPOIETIN PROTEIN AND USE THEREOF | 2007 |
|
RU2457217C2 |
| ANTIGENIC COMPOSITION AND THERAPEUTIC APPLICATION THEREOF FOR PREVENTING AND TREATING ONCOLOGICAL DISEASES, RECOMBINANT PLASMID DNA, PROVIDING SYNTHESIS OF HYBRID PROTEIN, AS WELL AS METHOD OF PRODUCING PROTEIN | 2013 |
|
RU2590701C2 |
| RECOMBINANT PRODUCTION OF HEPARIN BINDING PROTEINS | 2006 |
|
RU2385877C1 |
| METHOD OF INDUSTRIAL PURIFICATION OF ROMIPLOSTIM | 2021 |
|
RU2804622C2 |
